The recent French prospective ENVIE study has shed light on the protective properties of the monoclonal antibody nirsevimab (Beyfortus) in young infants against respiratory syncytial virus (RSV) related hospitalizations. This study, published in the New England Journal of Medicine, reported promising results which indicate that nirsevimab is effective in preventing RSV-associated bronchiolitis in infants under